4-三氟甲基苯肼盐酸盐 | 2923-56-0

• 物质功能分类: 化学试剂 - 有机试剂 - 肼
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-三氟甲基苯肼盐酸盐
• 中文别名: 4-(三氟甲基)盐酸苯肼；对三氟甲基苯肼盐酸盐；1-[4-(氟甲基)苯基]肼盐酸盐；4-三氟甲基苯肼HC；4-(三氟甲基)苯肼盐酸盐
• 英文名称: 4-(trifluoromethyl)phenylhydrazine hydrochloride
• 英文别名: p-trifluoromethylphenylhydrazine hydrochloride；[4-(trifluoromethyl)phenyl]hydrazine;hydrochloride
• CAS: 2923-56-0
• 化学式: C₇H₈F₃N₂*Cl
• mdl: MFCD00204233
• 分子量: 212.602
• InChiKey: WCAGNYIHAYOPSE-UHFFFAOYSA-N

物化性质

• 熔点：
  200 °C
• 稳定性/保质期：

  遵照规定使用和储存，则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.24
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  39.7
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2928000090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  存放于阴凉干燥处。

SDS

Name:	1-[4-(Trifluoromethyl)phenyl]hydrazine hydrochloride 95%+ Material Safety Data Sheet
Synonym:
CAS:	2923-56-0

Section 1 - Chemical Product MSDS Name:1-[4-(Trifluoromethyl)phenyl]hydrazine hydrochloride 95%+ Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
2923-56-0	1-[4-(Trifluoromethyl)phenyl]hydrazine	95+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 2923-56-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 200 - 202 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H8ClF3N2
Molecular Weight: 212.6

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 2923-56-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-[4-(Trifluoromethyl)phenyl]hydrazine hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 2923-56-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 2923-56-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 2923-56-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备方法：应用于医药中间体。

用途简介：

用途：应用于医药中间体。

反应信息

• 作为反应物：
  描述：

  4-三氟甲基苯肼盐酸盐 在 三乙胺 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 1.33h， 生成 4-chloro-1-(4-(trifluoromethyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidine
  参考文献：
  名称：

  Synthesis of 1,4-Disubstituted Pyrazolo[3,4-d]pyrimidines from 4,6-Dichloropyrimidine-5-carboxaldehyde: Insights into Selectivity and Reactivity

  摘要：

  Strategies for carrying out the reaction of 4,6-dichloropyrimidine-5-carboxaldehyde with both aromatic and aliphatic hydrazines to generate 1-substituted 4-chloropyrazolo[3,4-d]pyrimidines in a selective, high-yielding, and operationally simple manner are presented. For aromatic hydrazines, the reaction is performed at a high temperature in the absence of an external base. For aliphatic hydrazines, the reaction proceeds at room temperature in the presence of an external base. The observed selectivity and reactivity trends are rationalized through consideration of the proposed reaction mechanism. The 1-substituted 4-chloropyrazolo[3,4-d]pyrimidine products serve as versatile synthetic intermediates, through further functionalization of the 4-chloride moiety, enabling the rapid generation of a structurally diverse array of 1,4-disubstituted pyrazolo[3,4-d]pyrimidines.

  DOI：

  10.1055/s-0033-1338862
• 作为产物：
  描述：

  对三氟甲基苯胺 在 盐酸 、 sodium nitrite 、 tin(II) chloride dihdyrate 作用下， 以 水 为溶剂， 反应 3.0h， 生成 4-三氟甲基苯肼盐酸盐
  参考文献：
  名称：

  作为具有新型结合模式的 PDHc-E1 抑制剂的 2,6-二甲基-4-氨基嘧啶腙的设计、合成和抗真菌活性

  摘要：

  一系列新型 2,6-二甲基-4-氨基嘧啶腙5被合理设计和合成为丙酮酸脱氢酶复合物 E1 (PDHc-E1) 抑制剂。化合物5强烈抑制大肠杆菌（E.coli）PDHc-E1（IC 50值为 0.94–15.80 μM）。分子对接、定点诱变、酶促和抑制动力学分析表明，化合物5竞争性抑制 PDHc-E1 并以“直线”模式结合在大肠杆菌PDHc-E1 活性位点，这是一种新的结合模式. 在体外抗真菌试验中，大多数化合物5在50μg/ mL的显示针对六个测试植物病原性真菌，包括菌丝生长超过80％的抑制灰霉病，念珠菌fructigena，炭疽病菌，和葡萄座腔dothidea侵染。值得注意的是，5f和5i对M. fructigena 的效力是商业杀菌剂克菌丹和百菌清的1.8-380 倍。在体内，与商业杀菌剂戊唑醇相比，5f和5i控制M. fructigena的生长。因此，5f和5i对防治果蝇桃褐腐病具有潜在的商业价值。

  DOI：

  10.1021/acs.jafc.0c07701
• 作为试剂：
  描述：

  1-(4-tert-butylphenyl)-4-nitro-1H-indazole 在 氯化铵 、 4-三氟甲基苯肼盐酸盐 作用下， 以 乙醇 、 水 为溶剂， 以97%的产率得到1-(4-tert-butylphenyl)-4-amino-1H-indazole
  参考文献：
  名称：

  Identification, Synthesis, and Pharmacological Evaluation of Tetrahydroindazole Based Ligands as Novel Antituberculosis Agents

  摘要：

  The resurgence Of tuberculosis (TB), the incidence of drug-resistant strains of Mycobacterium tuberculosis (MTB), and the coinfection between TB and HIV have led to serious infections, high mortality, and it global health threat, resulting in the urgent search for new classes of antimycobacterial agents. Herein, we report the identification of a novel class of tetrahydroindazole based compounds as potent and unique inhibitors of MTB. Compounds 6a, 6m, and 6q exhibited activity in the low micromolar range against replicating Mycobacterium tuberculosis (R-TB) phenotype, with minimum inhibitory concentrations (MICs) of 1.7, 1.9, and 1.9 mu M, respectively, while showing no toxicity to Vero Ccells, Moreover, studies aimed to assess the in vitro metabolic stability of 6a and 6m in mouse liver microsomes and in vivo pharmacokinetic profiles in plasma levels gave satisfactory results. This research suggests that tetrahydroindazole based anti-TB compounds can serve its a promising lead scaffold in developing new drugs to combat tuberculosis infections.

  DOI：

  10.1021/jm901235p

文献信息

• [EN] SELECTIVE HDAC6 INHIBITORS<br/>[FR] INHIBITEURS SÉLECTIFS DE HDAC6
  申请人：ITALFARMACO SPA

  公开号：WO2018189340A1

  公开（公告）日：2018-10-18

  The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (HDAC6) enzyme.

  本发明涉及一种新型苯羟羟肟化合物的化学式(I)和(II)，以及其药用可接受的盐、异构体和前药，表现出对组蛋白去乙酰化酶6（HDAC6）酶具有高选择性抑制活性。
• [EN] NITROIMIDAZOXADIAZOCINE COMPOUNDS<br/>[FR] COMPOSÉS NITROIMIDAZOXADIAZOCINES
  申请人：ITHEMBA PHARMACEUTICALS PROPRIETARY LTD

  公开号：WO2013072903A1

  公开（公告）日：2013-05-23

  This invention relates to nitroimidazoxadiazocine compounds having the general Formula I, pharmaceutical compositions and uses of the same. The invention also relates to methods of making such nitroimidazoxadiazocine compounds of Formula I.

  这项发明涉及具有一般式I的硝基咪唑噁二唑环化合物，以及其药用组合物和用途。该发明还涉及制备一般式I的硝基咪唑噁二唑环化合物的方法。
• Continuous Flow Process For the Synthesis of Phenylhydrazine Salts and Substituted Phenylhydrazine Salts
  申请人：SHANGHAI HYBRID-CHEM TECHNOLOGIES

  公开号：US20190152896A1

  公开（公告）日：2019-05-23

  The present invention provided a continuous flow process for the synthesis of phenylhydrazine salts and substituted phenylhydrazine salts. Diazotization, reduction, acidic hydrolysis and salifying with acids are innovatively integrated together. Using acidic liquids of aniline or substituted aniline, diazotization reagents, reductants and acids as raw materials, phenylhydrazine derivative salts is obtained through the synthesis process, which is a three-step continuous tandem reaction including diazotization, reduction, acidic hydrolysis and salifying. The described synthesis process is a kind of integrated solutions, which is carried out in an integrated reactor. The feed inlets of the integrated reactor are continuously filled with raw materials. In the integrated reactor, diazotization, reduction, acidic hydrolysis and salifying are carried out continuously and orderly, and phenylhydrazine salts or substituted phenylhydrazine salts is obtained in the outlet of the integrated reactor without interruption. The total reaction time is no more than 20 min.

  本发明提供了一种连续流程，用于合成苯肼盐和取代苯肼盐。重氮化、还原、酸性水解和酸化与酸类创新地集成在一起。使用苯胺或取代苯胺的酸性液体、重氮化试剂、还原剂和酸类作为原料，通过合成过程获得苯肼衍生物盐，这是一个包括重氮化、还原、酸性水解和酸化的三步连续串联反应。所述的合成过程是一种集成解决方案，是在一个集成反应器中进行的。集成反应器的进料口连续填充原料。在集成反应器中，重氮化、还原、酸性水解和酸化被连续有序地进行，苯肼盐或取代苯肼盐在集成反应器的出口处获得，没有中断。总反应时间不超过20分钟。
• Catalytic Asymmetric Addition of Diorganozinc Reagents to Pyrazole‐4,5‐Diones and Indoline‐2,3‐Diones
  作者：Rong‐Hui Wang、Ya‐Ling Li、Hong‐Jiao He、You‐Cai Xiao、Fen‐Er Chen

  DOI：10.1002/chem.202005081

  日期：2021.3

  The catalytic enantioselective diorganozinc additions to cyclic diketones including pyrazolin‐4,5‐diones and isatins have been developed. In the presence of morpholine‐containing chiral amino alcohol ligand, the corresponding chiral cyclic tertiary alcohols were produced in good to excellent yields (up to 97 %) and enantioselectivities (up to 95 % ee). The notable feature of this protocol includes

  已经开发了对环二酮（包括吡唑啉-4,5-二酮和靛红）的催化对映选择性二有机锌。在含有吗啉的手性氨基醇配体存在的情况下，相应的手性环状叔醇以良好至极佳的收率（高达97％）和对映选择性（高达95％ee）生产。该方案的显着特征包括温和的反应条件，无路易斯酸添加剂和宽泛的官能团耐受性。
• Synthesis and Biological Evaluation of Chromenylurea and Chromanylurea Derivatives as Anti-TNF-α agents that Target the p38 MAPK Pathway
  作者：Xingzhou Li、Xinming Zhou、Jing Zhang、Lili Wang、Long Long、Zhibing Zheng、Song Li、Wu Zhong

  DOI：10.3390/molecules19022004

  日期：——

  A series of 1-aryl-3-(2H-chromen-5-yl)urea and 1-aryl-3-(chroman-5-yl)urea derivatives were designed, synthesized and evaluated for their inhibitory activities towards TNF-α production in lipopolysaccharide-stimulated THP-1 cells. The most active compound, 40g, inhibited TNF-α release with an IC50 value of 0.033 μM, which is equipotent to that of BIRB796 (IC50 = 0.032 μM).

  设计、合成并评估了一系列1-芳基-3-(2H-色烯-5-基)脲和1-芳基-3-(色满-5-基)脲衍生物对脂多糖刺激的THP-1细胞中TNF-α产生抑制活性。活性最高的化合物40g能以0.033 μM的IC50值抑制TNF-α的释放，与BIRB796的效力相当（IC50 = 0.032 μM）。